Abstract
CD8+ T cells are critical players in anti-tumor immunity. In higher-risk myelodysplastic neoplasms (HR-MDS) and acute myeloid leukemia (AML), CD8+ T cells exhibit altered functionality, however whether this affects disease course is poorly understood. Herein, we aimed to identify immune cell signatures in the bone marrow (BM) associated with disease progression and treatment outcomes. In-depth immunophenotypic analysis utilizing mass and flow cytometry on 104 pre-treatment BM samples from patients with myeloid neoplasms, revealed an increased frequency of a CD57+CXCR3+ subset of CD8+ T cells in patients with HR-MDS and AML who failed AZA therapy. Furthermore, increased baseline frequency (>29%) of the CD57+CXCR3+CD8+ T cell subset correlated with poor overall survival. We further engaged scRNA-seq to assess the transcriptional profile of BM CD8+ T cells from treatment-naïve patients. We observed an increased abundance of cells within cytotoxic CD8+ T lymphocytes (CTL) cluster in secondary AML compared to HR-MDS. Additionally, response to AZA was positively associated with enrichment of IFN-mediated pathways, whereas enhanced TGF-β signaling signature in CTL clusters was observed in non-responders. Our results support that targeting of CD8+ T cells with inhibitors of TGF-β signaling in combination with AZA is a potential future therapeutic strategy in HR-MDS and AML.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Hellenic Foundation for Research and Innovation (HFRI) under the HFRI Research Projects to Support Faculty Members& Researchers and Procure High-Value Research Equipment grant (HFRI FM17 452) and the General Secretariat for Research and Technology Management and Implementation Authority for Research, Technological Development, and Innovation Actions (MIA RTDI) (grant T2EDK 02288, MDS TARGET). TA and NEP are supported by the ERC under the European Union Horizon 2020 research and innovation program (grant agreement no 947975 to T. Alissafi) and from the Hellenic Foundation for Research and Innovation (H.F.R.I.) under the 2nd Call for H.F.R.I. Research Projects to support Post-Doctoral Researchers (Project Number: 166 to T. Alissafi) and the Sub-action 1. Funding New Researchers RRF: Basic Research Financing (Horizontal support for all Sciences) (Project number: 15014 to T. Alissafi). IPK is funded by the Academy of Medical Sciences (R2429101) and Rosetrees Trust (R2449101). TC is supported by the Deutsche Forschungsgemeinschaft (TRR332, project B4).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of the University Hospital of Alexandroupolis, under the reference number (877/23-10-2019).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Addion of figure 5, describing a further analysis of the data.
Data availability
The authors state that all data supporting this study are available in the main text or the supplementary material. The raw scRNA-sequencing data for this study have been deposited in the NCBI Gene Expression Omnibus repository and are accessible through accession number GSE250077. All other raw data can be provided by the authors upon reasonable request.